A Prospective Study of Chidamide Combined with Venetoclax in the Treatment of Newly Diagnosed Adult T-Lymphoblastic Lymphoma/T-Cell Acute Lymphoblastic Leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500110820

Enrollment

Unknown

Registered

2025-10-21

Start date

2025-10-25

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-Lymphoblastic Lymphoma/T-Cell Acute Lymphoblastic Leukemia

Interventions

Test group:Chidamide in Combination with Venetoclax

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. patients diagnosed with incipient acute T-lymphoblastoid lymphoma/leukaemia according to the 2016 WHO diagnostic criteria; 2. aged 18 to 65 years; 3. expected survival greater than or equal to 3 months; 4. ECOG score 0-2; 5. Voluntarily participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of other active malignant diseases (except skin basal cell tumours and surgically eradicated papillary thyroid tumours); 2. Patients with hypersensitivity to cedarbenazine; 3. Patients with severe and or uncontrolled infections. 4. Presence of severe cardiac disease: heart failure according to New York Heart Association (NYHA) functional class 3 or 4 cardiac insufficiency; or history of acute myocardial infarction within 6 months prior to screening; or uncontrolled arrhythmias and cardiac electrophysiological abnormalities such as SSS, third-degree AVB, QTc > 480 ms, ventricular tachycardia, persistent fast ventricular rate atrial fibrillation; or cardiac ultrasound showing severe structural cardiac abnormalities or Patients with left ventricular ejection fraction 3 times the upper limit of normal after baseline or hepatoprotective therapy, as well as patients with severe hepatitis and cirrhosis; 8. patients with severe renal pathology: eGFR 3 upper limit of normal value subjects; 10. pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
Complete Response Rate;Minimal Residual Disease Negativity Rate;	—

Secondary

Measure	Time frame
Incidence of Adverse Events;1-Year Overall Survival;1-Year Progression-Free Survival Rate;1-Year Relapse Rate;	—

Countries

China

Contacts

Public ContactHao Zhang

Affiliated hospital of jining medical university

gx-zhanghao@126.com+86 186 7876 6569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026